Alzheimer's disease

WASHINGTON — Engaging the primary care workforce in the diagnosis process of Alzheimer’s disease would accelerate the delivery of disease-modifying therapies, while easing the pressures already being experienced by overwhelmed neurology and geriatric practices, a new Rand report says. The... Read More

WASHINGTON — The Food and Drug Administration on Thursday gave its first approval to a drug that can slow the progression of Alzheimer's disease. In a press release the agency said its full approval of lecanemab, known by the brand... Read More

An experimental drug that removes a substance called amyloid — a toxic protein — from the brain appears to slow down Alzheimer's disease. The drug, lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800... Read More

WASHINGTON — Despite the results of a previous study, sildenafil (Viagra) and tadalafil (Cialis) may not be suitable candidates for treating dementia, according to the National Institutes of Health. The institute recently delved into the situation with its Drug Repurposing... Read More

WASHINGTON — Despite pressure to go another way, Medicare on Thursday evening announced it will only cover the new Alzheimer’s disease drug Aduhelm for people participating in a clinical trial. The decision came as something of a surprise as Medicare... Read More